Janus Kinase Inhibitor Market Demands and Growth Prediction till 2026

Janus Kinase Inhibitor Market – Size, Share, Outlook, and Opportunity Analysis 2018 - 2026
 
 
Janus Kinase Inhibitor Market-1
Janus Kinase Inhibitor Market-1
 
Spread the Word
Listed Under

Tag:
Janus Kinase Inhibitor

Industry:
Health

Location:
Seattle - Washington - US

Subject:
Reports

SEATTLE - July 5, 2019 - PRLog -- Janus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT (Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the transcription of genes which are critical for signal cascade involved in inflammatory and immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune disorders such as rheumatoid arthritis.

Janus Kinase Inhibitor Market Drivers

Jak inhibitors are increasingly preferred for industrial research due to their critical role in immune response signaling. For instance, in June 2018, Eli Lilly and Company announced approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an oral medication for rheumatoid arthritis in adults. Approval was granted for use of baricitinib in combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs) or as monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases the production of inflammatory cytokines, thereby inhibiting inflammatory response. Therefore, increasing launch of new drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period.

To Have A Snippet Of The Report, Request Sample: https://www.coherentmarketinsights.com/insight/request-sample/2553

Psoriatic arthritis is a form of arthritis, which is characterized by red patches of skin with silvery scales. Tofacitinib is a janus kinase inhibitor, which modulates cytokines that are required for signaling of inflammatory and immune response. Inclusion of new treatment options is expected to boost the global janus kinase inhibitor market growth over the forecast period. For instance, in December 2017, Pfizer Inc. received approval from the U.S. FDA for XELJANZ (TOFACITINIB) for treatment of adult patients suffering from psoriatic arthritis (PsA).

Janus Kinase Inhibitor Market Regional Analysis

The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic disease, which is characterized by inflammation of connective tissues such as cartilage and blood vessel lining. According to National Center for Biotechnology Information (NCBI), the highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000 person) during the period August 2013- September 2016. Therefore, high prevalence of SLE is expected to boost North America janus kinase inhibitor market growth over the forecast period.

Janus Kinase Inhibitor Market Key Players

Some of the key players operating in the global Janus kinase inhibitor market include, Eli Lilly and Company, Astellas Pharma Inc., Pfizer Inc., Baxter International Inc., Novartis International AG, Gilead Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte Corporation.

Janus Kinase Inhibitor Market Taxonomy

The global janus kinase inhibitor market is segmented on the basis of drugs, indication, distribution channel and regions.

By Drugs

• Baricitinib
• Tofacitinib
• Ruxolitinib
• Pipeline drugs

- Peficitinib

By Indication

• Rheumatoid arthritis
• Psoriatic arthritis
• Systemic lupus erythematosus
• Others

Get Full Access of This Business Report: https://www.coherentmarketinsights.com/ongoing-insight/janus-kinase-inhibitor-market-2553

About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

End
Email:***@coherentmarketinsights.com
Posted By:***@coherentmarketinsights.com Email Verified
Tags:Janus Kinase Inhibitor
Industry:Health
Location:Seattle - Washington - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Coherent Market Insights PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share